Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid…
$165.04+5.36%
报价 2026-11-13
市值
$22.11B
EV
$40.29B
PE (TTM)
129.2x
预期 PE (FY2026)
9.0x
52 周区间距高点 -65.1%
$151.64$473.29
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ALNYAlnylam Pharmaceuticals, Inc. | $22.11B | +5.4% | +45.1% | 81.7% | 129.2x | 85.2x | 44.1x | |
| REGNRegeneron Pharmaceuticals, Inc. | $98.82B | +0.5% | +31.5% | 85.8% | 19.8x | 15.1x | 26.6x | |
| CICigna Corporation | $78.26B | +0.2% | +5.9% | 9.5% | 11.7x | 7.8x | 9.5x | Cheap |
| CORCencora, Inc. | $68.51B | +3.0% | +4.6% | 4.3% | 23.2x | 13.6x | 15.1x | |
| CAHCardinal Health, Inc. | $64.97B | +1.1% | +4.1% | 4.3% | 31.6x | 16.9x | 11.9x | |
| EWEdwards Lifesciences Corporation | $61.61B | +1.3% | +12.7% | 78.1% | 44.5x | 32.6x | 43.3x | GARP |
| ARGXargenx SE | $60.37B | -2.2% | – | 89.9% | 38.2x | 39.0x | 58.5x | |
| BDXBecton, Dickinson and Company | $59.39B | +1.1% | +2.4% | 45.8% | 25.3x | 14.7x | 21.1x | |
| IDXXIDEXX Laboratories, Inc. | $55.48B | +0.9% | +10.8% | 62.9% | 47.6x | 33.7x | 42.8x | |
| 同行中位数 | – | – | +5.9% | 54.4% | 28.5x | 16.0x | 23.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。